Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPdR

Drug Profile

IPdR

Alternative Names: Ropidoxuridine

Latest Information Update: 15 Jan 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Research Foundation of State University of New York; Yale University
  • Developer SuperGen
  • Class Antivirals; Pyrimidine nucleosides; Radiation-sensitising agents; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Thymidine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anaplastic astrocytoma; Hepatitis B; Herpes simplex virus infections; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Jan 2007 Discontinued - Phase-I for Solid tumours in USA (PO)
  • 09 Jun 2006 IPdR has received orphan drug status for malignant glioma in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top